BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu M, Ekshyyan O, Herman Ferdinandez L, Rong X, Caldito G, Nathan CO. Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope 2011;121:978-82. [PMID: 21520111 DOI: 10.1002/lary.21724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Chen S, Yang SY, Chen Z, Tan Y, Jiang YY, Chen YZ. Drug sales confirm clinical advantage of multi‐target inhibition of drug escapes by anticancer kinase inhibitors. Drug Dev Res 2018;80:246-52. [DOI: 10.1002/ddr.21486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Sabo AN, Jannier S, Becker G, Lessinger JM, Entz-Werlé N, Kemmel V. Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology. Pharmaceutics 2021;13:470. [PMID: 33808416 DOI: 10.3390/pharmaceutics13040470] [Reference Citation Analysis]
3 Alam MM, Marin Fermin J, Spiller PT, Burnett C, Rong X, Moore-Medlin T, Maxwell CO, Khandelwal AR, Nathan CO. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma. Mol Carcinog 2021. [PMID: 34598317 DOI: 10.1002/mc.23357] [Reference Citation Analysis]
4 Weber H, Leal P, Stein S, Kunkel H, García P, Bizama C, Espinoza JA, Riquelme I, Nervi B, Araya JC, Grez M, Roa JC. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. Oncotarget 2015;6:31877-88. [PMID: 26397134 DOI: 10.18632/oncotarget.5047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
5 Bozorgi SS, Proctor GB, Carpenter GH. Rapamycin delays salivary gland atrophy following ductal ligation. Cell Death Dis 2014;5:e1146. [PMID: 24675464 DOI: 10.1038/cddis.2014.108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
6 Coppock JD, Lee JH. mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer. World J Otorhinolaryngol Head Neck Surg 2016;2:76-83. [PMID: 29204551 DOI: 10.1016/j.wjorl.2016.05.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, Martini M, Bianchi F, Maira G, Stancato L, De Maria R, Larocca LM, Pallini R. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. Neoplasia 2013;15:773-82. [PMID: 23814489 DOI: 10.1593/neo.13150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
8 Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia 2013;15:620-30. [PMID: 23730210 DOI: 10.1593/neo.13432] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
9 Patel H, Younis RH, Ord RA, Basile JR, Schneider A. Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin. J Oral Pathol Med 2013;42:250-6. [PMID: 22861817 DOI: 10.1111/j.1600-0714.2012.01196.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]